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Introduction: Our goal was to study whether influenza vaccination induced antibody
mediated rejection in a large cohort of solid organ transplant recipients (SOTR).
Methods: Serum anti-Human Leukocyte Antigen (HLA) antibodies were determined
using class I and class II antibody-coated latex beads (FlowPRATM Screening Test) by
flow cytometry. Anti-HLA antibody specificity was determined using the single-antigen
bead flow cytometry (SAFC) assay and assignation of donor specific antibodies (DSA)
was performed by virtual-crossmatch.
Results: We studied a cohort of 490 SOTR that received an influenza vaccination
from 2009 to 2013: 110 (22.4%) received the pandemic adjuvanted vaccine, 59 (12%)
within the first 6 months post-transplantation, 185 (37.7%) more than 6 months after
transplantation and 136 (27.7%) received two vaccination doses. Overall, no differences
of anti-HLA antibodies were found after immunization in patients that received the
adjuvanted vaccine, within the first 6 months post-transplantation, or based on the
type of organ transplanted. However, the second immunization dose increased the
percentage of patients positive for anti-HLA class I significantly compared with patients
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with one dose (14.6% vs. 3.8%; P = 0.003). Patients with pre-existing antibodies
before vaccination (15.7% for anti-HLA class I and 15.9% for class II) did not increase
reactivity after immunization. A group of 75 (14.4%) patients developed de novo anti-
HLA antibodies, however, only 5 (1.02%) of them were DSA, and none experienced
allograft rejection. Only two (0.4%) patients were diagnosed with graft rejection with
favorable outcomes and neither of them developed DSA.
Conclusion: Our results suggest that influenza vaccination is not associated with graft
rejection in this cohort of SOTR.
Keywords: cytomegalovirus, alloreactivity, donor specific antibodies, anti-human leukocyte antigen,
organ rejection
INTRODUCTION
Annual influenza vaccination is the most efficacious method in
reducing influenza complications inducing an optimal antibody
response in solid organ transplant recipients (SOTR) (1–7),
although with lower titers than those in the general population
(8). However, a percentage of SOTR, ranging from 1 to 47%, did
not respond adequately to influenza vaccine immunization, either
with an insufficient antibody response to vaccination or from
developing influenza infection after vaccination (9, 10). Different
strategies can be used to increase vaccination efficacy such as the
use of an adjuvanted vaccine that has been demonstrated to be
safe inducing a protective immune response in SOTR (11, 12).
Our group demonstrated that having detectable antibody titers
at vaccination improves the response to vaccination in SOTR
supporting the administration of a booster dose of the influenza
vaccine (13, 14), that was later demonstrated to be safe and
effective inducing an increased antibody response in a clinical
trial (15).
Despite the demonstrated efficacy of the influenza vaccination
in SOTR, different authors have suggested that exposure to
influenza antigens through vaccination could directly activate
alloreactive T and B cells (activating heterologous innate
immunity) (12, 13). Influenza vaccination can induce antibody
mediated rejection by increasing donor specific anti-human
leukocyte antigen (HLA) antibodies (DSA) (16–20). Recognition
of donor HLA in the graft by recipient’s T cells can stimulate
allograft rejection by the activation of a pro-inflammatory
response that includes the activation of B cells producing
DSA that can be associated with the development of chronic
allograft injury (21, 22). In addition, using strategies to increase
vaccination efficacy (high-dose vaccines, booster doses, and
adjuvanted vaccines) may contribute to increased allograft
rejection and graft dysfunction.
However, the available results concerning this issue are scarce.
Danziger-Isakov et al. in 2010 observed an increase in cellular
alloimmunity that was not translated into rejection in a study
including 17 transplant recipients (23). Similarly, a patient
awaiting kidney transplantation was documented with a specific
alloreactive kidney cell-specific response after a live attenuated
varicella vaccination (24). Regarding the humoral response, in
a study including 42 kidney transplant recipients that received
a single dose of a pandemic H1N1 ASO3 adjuvanted vaccine,
it was reported that de novo DSA and non-DSA anti-HLA
antibodies developed in five cases (11.9%), not linked to acute
rejections (25). In another study including two cohorts of 92
and 59 kidney transplant recipients that received one dose of
the seasonal influenza and two doses of the AS03-adjuvanted
H1N1 vaccine, respectively, the incidence of de novo anti-HLA
antibodies was very similar: 17.3 and 11.9%. However, two of
these patients (10%) presented thrombotic microangiopathy and
humoral rejection, within the next 6 months after vaccination,
partly attributed to the development of anti-HLA antibodies
(26). However, no events of rejection or de novo anti-HLA
antibodies were observed in a study including 66 kidney
transplant recipients that received trivalent influenza vaccines
(27). A recent study has shown no cross-reactivity between
HLA class I and II and several virus-specific human monoclonal
antibodies, suggesting that the emergence of anti-HLA antibodies
in the setting of viral infections or vaccination may be due
to bystander activation or dormant HLA specific B cells (28).
Our group has demonstrated that administering the influenza
vaccine 1 month post-transplantation is safe and efficacious (14),
reporting no episodes of rejection, however, we did not address
the de novo synthesis of DSA.
Based on these results, it would be necessary to conduct
large cohort studies in order to explore and clarify the safety
of vaccination and its relationship with the induction of DSA
and allograft rejection in SOTR. Thus, the aim of this study
was to determine whether influenza vaccination induces antibody
mediated rejection in SOTR.
MATERIALS AND METHODS
Patient Inclusion
A multicenter, prospective, longitudinal study of consecutive
SOTR receiving the influenza vaccines during four consecutive
influenza seasons: 2009–2010, 2010–2011, 2011–2012, and
2012–2013 was carried out. Patients were included from the
following 12 Spanish hospitals. Virgen del Rocío (Seville), Reina
Sofía (Córdoba), 12 de Octubre (Madrid), Gregorio Marañón
(Madrid), Ramón y Cajal (Madrid), Vall d’Hebron (Barcelona),
Bellvitge University (Barcelona), Clinic Hospital (Barcelona),
Cruces (San Vicente de Barakaldo), La Fe (Valencia), Virgen
Macarena (Seville), and Marqués de Valdecilla (Santander),
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all participating in the Spanish Network for the Research in
Infectious Diseases (REIPI).
Patients were excluded if they were less than 16 years old,
received the transplant less than 1 month ago, had allergies to
any of the vaccine components, developed acute rejection 15 days
before vaccination, or were pregnant. In patients vaccinated
from 2009 to 2012, serum samples were collected at vaccination
(baseline) and 5 weeks later. Patients from 2012 to 2013 season
came from the TRANSGRIPE clinical trial (15) that randomly
received either one or two doses of the vaccine 5 weeks apart.
In both arms, serum samples were collected at baseline, 5 weeks,
10 weeks, and 1 year after vaccination. Patients were followed-up
for 10 months to record possible adverse events, including events
of influenza disease.
Vaccines
Patients from 2009 to 2010 season received the 2009 (H1N1)pdm
monovalent MF59-adjuvanted vaccine containing the strain:
A/California/7/2009-H1N1 (Focetria, Novartis, Siena, Italy).
Patients from 2010 to 2011 and 2011 to 2012 seasons received
the trivalent non-adjuvanted inactivated vaccine (Gripavac,
Sanofi-Pasteur MSD, Madrid, Spain) containing the strains:
A/California/7/2009-H1N1, A/Perth/16/2009-H3N2, and
B/Brisbane/60/2008. Patients from 2012 to 2013 season
were randomly assigned to received one or two doses of the
trivalent non-adjuvanted inactivated vaccine (Mutagrip, Sanofi-
Pasteur MSD) with the strains: A/California/7/2009-H1N1,
A/Victoria/361/2011-H3N2, and B/Wisconsin/1/2010.
Clinical Parameters and Definitions
Baseline characteristics, immunological and clinical response,
and adverse effects, including graft rejection and mortality, were
recorded. Follow-up clinical parameters were collected using
a standardized questionnaire. Graft rejection was confirmed
histologically if biochemical or functional abnormalities were
detected. Vaccinated patients included all individuals who had
received the seasonal influenza vaccine in the previous year or
any vaccine in the previous month. Rejection was defined using
the Banff criteria (29). Adverse events were assessed according to
established criteria (30).
HLA Determination
We first carried out a sample screening to determine the presence
of anti-HLA antibodies in serum using class I and class II
antibody-coated latex beads (FlowPRATM Screening Test, One
Lambda, Inc., Canoga Park, CA, United States) by flow cytometry
according to the manufacturer’s instructions. A doubling of
the PRA percentage at any time point after vaccination from
baseline or a 10% increase was considered a positive alloantibody
response, and we used single antigen beads to assess for specificity
of the alloantibody for positive responses. On the serum samples
in which anti-HLA class I and/or class II antibodies were detected
in the screening, the specificity of the anti-HLA antibodies
was determined using the single-antigen bead flow cytometry
(SAFC) assay (Lifecodes LSATM class I, LSA1, and/or class
II, LSA2, Tepnel). Phycoerythrin-conjugated goat anti-human
IgG antibody was used as a secondary antibody. Samples were
analyzed on a Life Match fluoroanalyzer using Luminex 100
IS v 2.3 as software for data acquisition and Quicktype for
Lifematch as analysis software. Positive and negative control
sera and beads were included in each test. For validation, all
controls met the manufacturer’s specifications. To determine if
an individual bead was recognized by a serum sample, only the
Median Fluorescent Intensity (MFI) raw value was considered.
A sample was considered positive to a specific bead when the MFI
raw value was greater than 1500.
Assignation of DSA (Virtual
Crossmatches): Donor HLA Typing
Samples of all deceased donors were routinely typed before
recipient selection in loci HLA-A∗, B∗, and DRB1∗ using
the PCR-specific sequence primers (SSPs) system (AllSetTM
Gold HLA-A, HLA-B, and HLA-DR Low Resolution SSP kits;
Invitrogen Ltd., Paisley, United Kingdom). If antibodies against
HLA-C, DQ, or DP were detected by SAFC in a pre-transplant
patient serum, the donor HLA genotype was performed in the
corresponding locus using a PCR-SSP system (AllSetTM Gold
HLA-C and HLA-DQ Low Resolution SSP kits and AllSetTM
Gold HLA-DPB1 High resolution SSP kit; Invitrogen Ltd). High
resolution typing was performed if it was necessary to establish
whether the anti-HLA antibodies were DSA (SSP Gold High
resolution kits; Invitrogen Ltd), determining whether SAFC
detected anti-HLA antibodies in a particular patient were DSA
comparing with donor HLA typing.
Influenza Virus Microneutralization
Assays
Microneutralization assays were performed as previously
described (8, 14).
Statistical Analysis
A descriptive statistical analysis was performed. Continuous
variables were expressed as median and interquartile ranges.
Rates of positive patients for anti-HLA class I and II were
compared using the McNemar or Chi square tests and the
Bonferroni correction was applied when appropriate. The
multivariate logistic regression analysis of factors potentially
associated with anti-HLA response included significant variables
in the bivariate analyses and those clinically relevant variables
(time from transplantation to influenza vaccination, type of
transplant, and the number of doses of influenza vaccine
administered). For immunogenicity analysis geometric mean
antibody titer and the T-Student test were used. Results
were analyzed by PASW Statistic 18.0.1 software. Statistical
significance was established as a p-value <0.05.
RESULTS
Patient Cohort
A total of 490 SOTR were included in the study, 110 (22.4%)
patients received the 2009 (H1N1)pdm adjuvanted vaccine,
and 380 (77.6%) received a non-adjuvanted seasonal influenza
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TABLE 1 | Patient baseline characteristics and comorbidities.
Variables Total n = 490
Male- n (%) 315 (64.3)
Age (median, IQR) 56.0 (46–63)
Type of transplant
Kidney- n (%) 143 (29.2)
Liver- n (%) 155 (31.6)
Heart- n (%) 95 (19.4)
Lung -n (%) 92 (18.8)
Combined-n (%) 5 (1.0)
Immunosuppressive therapy
Tacrolimus- n (%) 340 (69.4)
Mycophenolate mofetil-n (%) 366 (74.7)
Cyclosporine- n (%) 106 (21.6)
mTOR inhibitors- n (%) 65 (13.3)
Comorbidities- n (%)
Chronic liver disease- n (%) 47 (9.6)
Diabetes mellitus- n (%) 133 (72.9)
Chronic heart disease- n (%) 99 (20.2)
Chronic kidney disease- n (%) 68 (8.8)
Hypogammaglobulinemia- n (%) 20 (4.1)
Median time since transplantation-months (IQR) 36.5 (12.0–90.1)
Previous season influenza vaccination- n (%) 360 (73.4)
Data are presented as n (%) unless otherwise indicated, IQR, interquartile range.
vaccine. A subgroup of 266 patients receiving the non-adjuvanted
vaccine, were randomized to receive one dose; 130 (48.8%), or
two doses; 136 (51.2%). Additionally, of the 490 SOTR, 59 (12%)
were immunized within the first 6 months post-transplantation,
and 431 (88%) after 6 months. Baseline characteristics and
clinical parameters of the cohort are described in Table 1. The
median age of the cohort was 56 years (IC range 46–63) and the
liver was the most frequent transplanted organ (31.6%). As an
immunosuppressive regime, most patients (91%) had calcineurin
inhibitors (69.4% tacrolimus and 21.6% cyclosporine) and 74.7%
mycophenolate mofetil. Most patients (73.4%) had received the
influenza vaccine the previous flu-season.
Anti-HLA Antibody Response
For all 490 SOTR, anti-HLA antibody response was screened
before vaccination (baseline) and 5 weeks after each dose. At
baseline, 79 of the patients (15.7%) were positive for anti-HLA
class I antibodies and 78 (15.9%) for anti-HLA class II antibodies.
None of the patients with pre-existing antibodies had an increase
in reactivity after vaccination. The proportion of patients with
positive anti-HLA class I and/or class II antibodies did not
significantly increase 5 weeks after vaccination (Tables 2, 3 and
Figure 1A). The number of patients with positive anti-HLA class
I and/or class II did not significantly increase either in the group
of patients vaccinated during the first 6 months of the transplant
(Tables 2, 3 and Figure 1C) or in those patients who received an
adjuvanted vaccine (Table 2, 3 and Figure 1B).
However, among patients receiving two doses of the trivalent
non-adjuvanted inactivated vaccine, the proportion of patients
with anti-HLA class I antibodies significantly increased 5 weeks
after the second vaccine dose (4.6% vs. 14.6%, P = 0.003;
Table 2 and Figure 1D), but no increase was observed for anti-
HLA class II antibodies. No increase of anti-HLA class I and
class II antibodies was noted 1 year after the second vaccination
(Tables 2, 3).
The incidence of anti-HLA antibodies stratified by the organ
at baseline and during follow-up are detailed in Tables 2, 3 and
Figures 1E,F. The levels of anti-HLA antibodies significantly
decreased during the follow-up for all patients with class I
antibodies at baseline, at 5 weeks, 10 weeks, and 1 year
after immunization (54.29% vs. 22.88%, 21.4%, and 8.84%,
respectively) while no differences were observed for patients with
anti-HLA class II antibodies at baseline.
Analysis of Patients With Increased
Anti-HLA Antibody Response After
Vaccination
A total of 75 patients (15.3%) developed de novo or had a 10%
increase in anti-HLA antibodies after vaccination: 52 patients
(69.3%) at 5 weeks, 19 (25.3%) at 10 weeks, and 4 (5.3%) at
1 year. Of them, 41 patients became positive for anti-HLA
class I antibodies after vaccination: 11 (26.8%) had received
the influenza A/(H1N1)pdm adjuvanted vaccine, 2 (4.8%) were
vaccinated within the first 6 months after transplantation,
17 (41.4%) received one dose later than 6 months after the
transplant, and 11 (26.8%) received two doses of the vaccine.
A group of 25 patients became positive for anti-HLA class II
after vaccination: 4 (16.0%) received the pandemic adjuvanted
vaccine, 12 (48.0%) received one dose more than 6 months after
transplantation, and 9 (36.0%) received two doses. A group of
9 patients became positive for both anti-HLA class I and II
antibodies after vaccination: 2 (22.2%) received the pandemic
adjuvanted vaccine, 5 (55.5%) two doses, and 2 (22.2%) were
vaccinated within the first 6 months post-transplantation. The
distribution by organ was: 7 (77.7%) received a liver transplant,
1 (11.1%) kidney, and 1 (11.1%) heart.
In this group of 75 patients that developed anti-HLA
antibodies after immunization no significant differences in the
levels of MFI were found at 5 weeks after vaccination compared
with baseline for anti-HLA class I (2477.78 vs. 2766.69, P = 0.647)
or class II antibodies (6621.84 vs. 5164.7, P = 0.157); at 10 weeks
after vaccination for anti-HLA class I (2477.78 vs. 12023.66,
P = 0.084) and class II (6621.84 vs. 7919, P = 0.277) antibodies,
and at 1 year after vaccination for anti-HLA antibodies (9510.66
vs. 16609.50, p = 0.378).
Correlation Between Neutralizing
Antibody Levels and Development of
Anti-HLA Antibodies
No correlation was found between the immunological efficacy
(measured by GMT after the immunization) of the influenza
vaccine and developing de novo anti-HLA antibodies (Table 4).
Multivariate Analysis
A multivariate logistic regression analysis was performed to
evaluate possible confounding factors involved in the production
Frontiers in Immunology | www.frontiersin.org 4 October 2020 | Volume 11 | Article 1917
fimmu-11-01917 October 3, 2020 Time: 17:30 # 5
Cordero et al. Influenza Vaccination and Graft Rejection
TABLE 2 | The percentage of patients that were positive for anti-HLA class I antibodies for each of the indicated vaccination strategies.
% HLA Class I
N* Baseline 5 weeks post-vaccination N** 10 weeks post-vaccination 1 year post-vaccination
Total cohort n-(%) 490 77 (15.7) 66 (13.4) 260 36 (13.5) 9 (4.9)
Vaccine composition n-(%)
Adjuvanted 110 17 (15.4) 21 (19.0)
Non-adjuvanted 380 60 (15.7) 45 (11.8)
Time from Transplant to vaccination n-(%)
≤6 months 59 9 (15.2) 7 (10.1)
>6 months 431 68 (15.7) 59 (13.6)
Number of vaccine doses n-(%)
One dose 130 11 (8.0) 14 (10.2) 130 17 (12.5) 4 (2.9)
Two doses 136 6 (4.6) 5 (3.8) 136 19 (14.6)* 5 (3.8)
Type of transplant n-(%)
Kidney 153 35 (24.5) 31 (24.4) 64 11 (17.1) 5 (7.8)
Liver 155 25 (16.1) 16 (11.1) 70 8 (11.5)** 1 (1.4)
Heart 95 11 (11.6) 11 (12.9) 55 7 (12.7) 1 (1.8)
Lung 92 5 (5.4) 5 (5.9) 75 9 (12.0) 1 (1.3)
Combined (liver-kidney) 5 1 (20.0) 3 (60.0) 3 1 (33.3) 1 (33.3)
Parameters were compared using the McNemar test or Chi-square test when appropriate. *P = 0.003, **P = 0.043. N*, number of individuals analyzed at baseline and at
5 weeks post-vaccination. N**, number of individuals analyzed at 10 weeks and at 1 year post-vaccination.
TABLE 3 | Influenza vaccination strategy and anti-HLA class II antibody production.
% HLA Class II
N* Baseline 5 weeks after vaccination N** 10 weeks after vaccination 1 year after vaccination
Total cohort n-(%) 490 78 (15.9) 63 (14.0) 260 28 (10.8) 19 (7.1)
Vaccine composition n-(%)
Adjuvanted 110 16 (14.5) 19 (17.3)
Non-adjuvanted 380 62 (16.3) 51 (13.4)
Time from Transplant to vaccination n-(%)
≤6 months 59 9 (15.3) 7 (11.8)
>6 months 431 69 (16.0) 62 (14.6)
Number of vaccine doses n-(%)
One dose 130 9 (6.6) 13 (9.5) 130 11 (8.0) 10 (7.3)
Two doses 136 13 (10.0) 9 (6.9) 136 17 (13.0) 9 (6.9)
Type of transplant n-(%)
Kidney 153 31 (21.7) 23 (18.1) 64 9 (14.0) 9 (14.0)
Liver 155 29 (18.7) 23 (15.9) 70 6 (8.6) 3 (4.3)
Heart 95 12 (12.6) 10 (11.7) 55 6 (10.9) 3 (5.4)
Lung 92 4 (4.3) 5 (5.9) 75 6 (8.0) 3 (4.0)
Combined (liver-kidney) 5 2 (40.0) 2 (40.0) 3 1 (33.3) 1 (33.3)
Parameters were compared using the McNemar test or Chi-square test when appropriate. No differences were observed in all the analyses made. N*, number of
individuals analyzed at baseline and at 5 weeks post-vaccination; N**, number of individuals analyzed at 10 weeks and at 1 year post-vaccination.
of anti-HLA class-II antibodies 5 weeks after the last dose
of influenza vaccine and 1 year after vaccination (Table 5).
Having detectable HLA antibodies before vaccination was the
only factor significantly associated with an increase of anti-
HLA class I antibodies [OR = 6.91 (3.6–13.29), p = 0.004]
and class II [OR = 237.44 (20.08–2341.47), p < 0.001] at
5 weeks after the second vaccine dose. Having anti-HLA
antibodies was also related with developing anti-HLA class II
antibodies [OR = 48.40 (10.20–229.54), p < 0.01] at 1 year after
vaccination. However, other variables such as the administration
of the adjuvanted influenza vaccine or the administration of
a seasonal influenza vaccination within the first months after
transplantation, were not related with later development of anti-
HLA, class I or class II antibodies. Our results also showed
that a second dose of the seasonal influenza vaccine was
not related to the later development of anti-HLA antibodies,
including class II antibodies, which have been related to graft
rejection after transplantation. In our SOTR cohort, receiving
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FIGURE 1 | The percentage of patients that were positive for anti-HLA class I or II antibodies: (A) Before and after influenza vaccination; (B) Comparing patients
receiving the adjuvanted or non-adjuvanted vaccine at the indicated time of receiving the influenza vaccine immunization; (C) Comparing patients that received the
influenza vaccine within the first 6 months (<6 months) or after 6 months (>6 months) post-transplantation; (D) Comparing patients receiving one or two doses of
the influenza vaccine; (E) Comparing patients based on the organ type for anti-HLA class I antibodies; (F) Comparing patients based on the organ type for anti-HLA
class II antibodies. Notes: Baseline refers to the time of administration of the first dose of influenza vaccine, 5 weeks refers to 5 weeks after the first dose, 10 weeks
refers to 5 weeks after the second dose and 1 year refers to 1 year after immunization.*P < 0.05, statistically significant difference.
two doses of the influenza vaccination did not increased the
risk of developing class I and II anti-HLA antibodies 1 year
after vaccination.
Donor Specific Antibody Production
Of the 75 patients that developed anti-HLA antibodies in
response to vaccination, only 5 patients had DSA (Table 6).
One received a combined liver-kidney transplantation and
one dose of the 2009 (H1N1)pdm adjuvanted influenza
vaccine 57 months after transplantation and developed DSA
class I (subtype A∗01:01, 02:02) antibodies 5 weeks after
vaccination. The second patient was a kidney recipient who
received two doses of the non-adjuvanted influenza vaccine
14 months after transplantation, and developed DSA class II
(subtype DRB1∗01:03 and DRB3) antibodies 5 weeks after
the second immunization. In this case DSA was already
present in the patient’s serum at baseline and increased
after vaccination.
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TABLE 4 | Geometric mean titer (GMT) after vaccination and anti-HLA class I and II antibodies after vaccination.
Positive for anti-HLA class I
post-vaccination
Positive for anti-HLA class II
post-vaccination















































GMT, geometric mean titer. Parameters were compared using T-Student test.
TABLE 5 | Regression model of factor influencing positive of anti-HLA class I and II.
Variables % HLA class I positives % HLA class II positives
10 weeks after vaccination 1 year after vaccination 10 weeks after vaccination 1 year after vaccination
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
First 6 months from
Transplant (yes vs. no)
1.17 (0.30–4.48) 0.812 0.501 (0.054–4.60) 0.541 1.17 (0.16–8.15) 0.873 2.36 (0.58–9.58) 0.229
Type of Transplant
Liver 1 1 1 1
Kidney 1.19 (0.27–5.15) 0.817 0.39 (0.043–3.55) 0.404 1.87 (0.26–13.29) 0.529 0.90 (0.19–4.15) 0.892
Heart 2.46 (0.76–8.00) 0.133 0.23 (0.026–2.14) 0.200 0.69 (0.07–6.81) 0.757 0.29 (0.054–1.56) 0.151
Lung 4E10 (0.00–) 0.999 21.94
(0.93–515.02)
0.055 2E9 (0.00–) 0.999 2.07 (0.02–161.77) 0.743
Mycophenolate (yes vs.
no)
1.31 (0.43–4.00) 0.632 1.54 (0.28–8.36) 0.617 19.48
(0.93–404.82)
0.055 0.79 (0.22–2.82) 0.717
Two doses of
vaccination (yes vs. no)
2.43 (0.67–8.75) 0.174 2.36 (0.50–11.06) 0.273 16.16
(0.70–369.04)
0.081 0.79 (0.24–2.59) 0.700
Anti-HLA positive at
baseline (yes vs. no)





CI, confidence interval; OR, odds ratio. Parameters were compared using adjusted logistic regression.
TABLE 6 | Clinical parameters of patients developing DSA.
Months from
transplantation







57 Combined Liver-Kidney Class I HLA I-A 01:01 5 weeks −83.1% No Favorable
14 Kidney Class II HLA II DRB1*01:03 10 weeks −40.2% No Favorable
52 Lung Class II HLA II DR52 1 year 37.4% No Favorable
49 Lung Class II HLA II DQ9, DQ2 1 year 83.55% No Favorable
6 Kidney Class II HLA DQ7, DQ4 1 year Undetectable at
baseline
No Favorable
The other three patients developed DSA 1 year after
vaccination, one of them was a lung recipient who received two
doses of the influenza vaccine 52 months after transplantation
and developed DSA class II (subtype DR52) antibodies.
A second lung recipient received one dose of the non-adjuvanted
vaccine 49 months after transplantation and developed DSA
class II (subtype DQ2 and DQ9) antibodies. A third kidney
recipient received one dose of the vaccine 6 months after
transplantation and developed DSA class II (subtype DQ4
and DQ7) antibodies. None of them had graft rejection
during the follow-up.
In one patient the specificity of anti-HLA antibodies was not
determined because donor genotyping was not available.
No difference in immune suppression was observed
between patients who did and did not develop anti-HLA I
and II antibodies.
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Rejection Episodes
Only two (0.4%) patients of the cohort studied were diagnosed
with graft rejection during the follow-up. A lung recipient
(12 months after transplantation) was diagnosed with acute
graft rejection 10 days after receiving one dose of the trivalent
influenza vaccine. A decrease in FEV1 had been detected before
vaccination coinciding with sub-therapeutic levels of tacrolimus.
A heart recipient (6 months after transplantation) was diagnosed
with acute cellular graft rejection IIIA 70 days after receiving
a second dose of non-adjuvanted influenza vaccine. Neither
of them developed DSA and no other circumstances indicated
the presence of acute rejection. Both patients had favorable
outcomes after rejection. No differences in pre- and post-
vaccination lymphocyte counts were found (1524.8 ± 808.6/ml
vs. 1500.3 ± 753.8/ml, P > 0.05). In patients with rejection,
lymphocytosis after vaccination was not observed.
DISCUSSION
The presents study suggest that the clinical effects of
allostimulation on graft rejection seems extremely low,
supporting the safety of different strategies to optimize influenza
vaccination response in SOT recipients. Moreover, we observed
that the production of DSA antibodies is not related to time
elapsed after a transplant or the use of adjuvant or booster doses
of the influenza vaccine.
Antibody-mediated rejection is a major determinant
of allograft loss. The development of de novo DSA after
transplantation has been associated with decreased allograft
survival (31, 32). The safety of the influenza vaccination in
transplant patients has been questioned since some studies
have suggested that antigens included in the influenza vaccine
composition may cross-react with alloantigens involved in graft
rejection, raising the risk of a vaccination-induced alloimmune
response (27, 33). In the present study we have analyzed different
strategies of influenza vaccination and their influence on the
production of DSA and/or rejection in SOT recipients and
evaluated the clinical relevance of DSA.
Higher MFI levels have been associated with poorer outcomes.
In our cohort, although the method used to measure anti-HLA
antibody levels is semiquantitative, having anti-HLA antibodies
before immunization did not predispose patients to an increased
risk for developing anti-HLA antibodies after vaccination
considering the MFI levels before and after vaccination.
We also found that patients receiving the vaccine within
6 months after transplantation had less of a alloreactive
response, which may be related with the higher levels of
immunosuppressors during this period.
In the present report, the immune response triggered against
influenza antigens in the vaccine composition was not associated
with the production of de novo DSA or with rejection, with
similar outcomes in the different types of transplants studied.
Contrary to what has been previously suggested (26), our
results show that having an adjuvant in the composition of the
vaccine has little or no influence on alloimmune response and
graft rejection.
The proportion of graft rejection was low in our series,
despite all patients being closely followed up, and biopsies were
performed in cases that biochemical or functional abnormalities
were detected. However, subclinical rejection could not be ruled
out. The low incidence of graft rejection could be also explained
by the time elapsed since transplantation, more than 1 year for
three-quarters of the patients included.
In general, increased risk of graft rejection and lower vaccine
efficiency occurs during the first months of transplantation (4,
34). In a previous report we found a similar response to influenza
vaccination in patients vaccinated before or after 6 months post-
transplantation (14). In this study, the immunological impact of
influenza vaccination, assessed by the production of anti-HLA
antibodies and DSA, was evaluated, concluding that the timing
of influenza vaccinations after transplantation had no influence
on the production of anti-HLA antibodies, DSA, or rejection.
Regarding the risk of an alloimmune response against
influenza antigens after the administration of a booster dose, we
found that although a second immunization dose was associated
with developing more anti-HLA class I antibodies, no differences
were found regarding the production of DSA and graft rejection.
It is not clear in the literature whether DSA have clinical
relevance since most of the results available are retrospective.
Although some DSA may be associated with a rapid decline in
graft function, it may take months to years before a pathologic
correlation is seen in others (35).
Other authors have previously studied the induction of donor-
specific HLA antibodies after vaccination using the conjugated
Streptococcus pneumonia vaccine. Their results show that no
de novo HLA antibodies were developed in kidney recipients,
however, they suggested that female kidney transplant recipients
may be more susceptible to the induction of HLA antibodies after
vaccination (36, 37). In addition, a recent meta-analysis suggested
no effect on the development of de novo donor-specific antibodies
and no increases in acute rejection after vaccination in SOT
recipients. While most of the papers included studied influenza
vaccination, measles, hepatitis B, varicella, tetanus, diphtheria,
and polio vaccination have also been assessed (38).
Some authors have proposed that rejection is linked to
reaching a threshold of alloreactive memory T cells (33). In line
with this idea, we found that patients exposed twice to influenza
antigens were more prone to have an anti-HLA class I antibody.
However, only one SOTR developed de novo anti-HLA DSA
antibodies after a second immunization, and this patient had a
favorable outcome, with no rejection episodes.
The HLA system is highly polymorphic with numerous alleles.
Class II antibodies have been more frequently related to graft
rejection, particularly those targeting HLA DQ antigens (39, 40).
Some authors suggest that there may be a higher risk of acute
and chronic allograft rejection when de novo DSA are found on
routine monitoring at any time post-transplantation (41). Our
results do not support this idea since, only four patients had
increased DSA class II levels after influenza vaccination, and none
of them had clinical or functional graft rejection. Additionally,
only two patients had graft rejection in this cohort and none
developed de novo DSA after influenza vaccination suggesting
that rejection was not related to influenza immunization.
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Some limitations might be considered. Firstly, we were unable
to establish the timing after immunization for the development
of antibodies since no samples were collected between 10 and
56 weeks. Secondly, biopsies were only performed if rejection was
suspected in all but heart transplant recipients, who had regular
histological studies. In patients who developed DSA, biopsies
were not performed and therefore subclinical rejection can not
be ruled out. In any case, it had no impact on graft function
as observed during follow-up. Thirdly, this paper analyses the
production of HLA antibodies and its association with antibody
mediated rejection. However, it does not exclude the possibility
of vaccine induced T cell allorecognition. Finally, no information
regarding other types of vaccines different from influenza or
pneumococcus is available which limits the extrapolation of these
results to other vaccines.
In summary, our results suggest no association between
influenza vaccination and graft rejection in SOTR. In addition,
strategies to improve the immune response after vaccination such
as earlier vaccination after transplantation, the use of an adjuvant
in the composition of the vaccine, or the use of a booster dose are
effective and safe and may not increase rates of rejection.
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